脑心清介导 AMPK/SIRT1 通路促进脂肪酸氧化改善非酒精性脂肪肝.

Objective This study aims to investigate the therapeutic effect and mechanism of Naoxinqing on non- alcohol fatty liver disease (NAFLD) induced by a high-fat diet through network pharmacology, molecular docking and in vitro and in vivo experiments. Methods ApoE-/- mice were given a high-fat diet for 12 weeks to establish the NAFLD model, followed by a 12-week Naoxinqing administration. To evaluate the therapeutic effect of Naoxinqing on NAFLD induced by a high-fat diet, biochemical and histopathological experiments were performed, including assessment of blood lipids, liver function, serum inflammatory factors, as well as Hematoxylin and eosin (HE), Oil red O, and Sirius red staining of liver. Subsequently, network pharmacology and molecular docking techniques were employed to predict the key targets of Naoxinqing. Finally, the mechanism of Naoxinqing was validated by Western Blot in HepG2 cells and liver tissue. Results The results of serum biochemistry and liver tissue pathology showed that Naoxinqing can significantly improve high-fat diet-induced hepatic lipid accumulation, hepatocellular injury, and inflammation. Network pharmacology and molecular docking analysis results suggested that Naoxinqing may affect lipid metabolism through the AMP-activated protein kinase (AMPK) /Sirtuin 1 (SIRT1) pathway. Finally, in vitro cell experiment confirmed that the main mechanism of Naoxinqing is to activative the AMPK/SIRT1 pathway, upregulate the expression of downstream carnitine palmitoyltransferase 1 (CPT1A), promote fatty acid oxidation, and ultimately improve NAFLD. Conclusion This study demonstrated that Naoxinqing improved NAFLD by promoting fatty acid oxidation through the activation of the AMPK/SIRT1 pathway. [ABSTRACT FROM AUTHOR]